Search the Newsreel

Vivani Medical: Q2 Earnings Snapshot

Renaissance Technologies (UTMD) discloses 5.52% ownership in Utah Medical Products

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 175,814 shares, or 5.52%, in Utah Medical Products Inc. as of June 30, 2026. Both entities hold sole voting and dispositive power over these shares. The filing, a Schedule 13G/A, …

IceCure Medical (Nasdaq: ICCM) updates filing for 533,334 warrant-share resales

IceCure Medical Ltd. has filed a post-effective amendment to its Form F-1 to update financial information and maintain the effectiveness of a resale registration. This filing concerns the potential resale of up to 533,334 Ordinary Shares by existing selling shareholders, which are issuable upon …

IceCure Medical (ICCM) details 324,802-share warrant issuance and $9.7M potential proceeds

IceCure Medical Ltd. has filed a post-effective amendment to register the issuance of up to 324,802 Ordinary Shares upon the exercise of outstanding warrants from a previous rights offering. The exercise includes warrants at $30.00 per share and pre-funded warrants at $0.003 per share, …

Profound Medical (PROF) launches global ‘Let’s Huddle’ prostate patient community

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced the launch of "Let's Huddle," a global patient advocacy and community initiative for men navigating prostate care. Led by former NFL player and prostate cancer survivor Leonard Wheeler, the program aims to provide education, peer support, and resources …

Adagio Medical updates investor presentation; expects FDA PMA approval for vCLAS in Q4 2026, $7.7M cash

Adagio Medical has released an updated investor presentation detailing its ULTA technology and clinical program. Key highlights include the full enrollment of the FULCRUM‑VT pivotal trial, projected FDA PMA approval for its first-gen vCLAS in Q4 2026, and $7.7 million in cash as of …

Mobia Medical (MOBI) investors report up to 11.6% ownership in Schedule 13G

U.S. Venture Partners XII, L.P., Presidio Management Group XII, L.L.C., and Casey M. Tansey have filed a Schedule 13G disclosing significant ownership stakes in Mobia Medical, Inc. (MOBI). U.S. Venture Partners XII, L.P. holds 5.7%, Presidio Management Group XII, L.L.C. holds 10.9%, and Casey …

Tenon Medical Q2 Revenue Rises 127% to $1.3 Million

Tenon Medical (TNON) reported a significant increase in its Q2 2026 revenue, rising 127% to $1.3 million, with gross profit up 232% to $0.8 million. The company also announced FDA 510(k) clearance for its updated Catamaran SI Joint Fusion System and completed a $4.2 …

MPT Declares Regular Quarterly Dividend

BIRMINGHAM, Ala., August 13, 2026--(BUSINESS WIRE)--MPT (the "Company" or "MPT") (NYSE: MPT) today announced that its Board of Directors declared a regular quarterly cash dividend of $0.09 per share of common stock to be paid on October 8, 2026, to stockholders of record on …

Modular Medical (MODD) investor group discloses 6.23% stake and warrant overhang

An investor group led by Bleichroeder LP has disclosed a 6.23% beneficial ownership stake in Modular Medical, Inc. (MODD), totaling 336,986 common shares with sole voting and dispositive power. The group also holds warrants for an additional 110,092 shares, but their exercise is subject …

Vivani Medical (VANI) widens GLP‑1 pipeline, funds runway into Q2 2027

Vivani Medical (VANI) has reported a net loss of $6.4 million for Q2 2026 and $13.2 million for the first half of 2026, with cash and equivalents totaling $19.9 million, which is projected to fund operations into Q2 2027. The company is advancing its …

Form 8K Vivani Medical Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Vivani Medical Inc. on August 13th, as tracked by Investing.com. The brief mention indicates a financial disclosure event for the company, with the stock symbol VANI noted to have experienced a -2.19% change.

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Vivani Medical reported its second-quarter 2026 financial results, highlighting significant progress in its clinical development, including the successful dosing of all participants in its SLIM-1 Phase 1 trial for NPM-139, a semaglutide implant for chronic weight management. The company also announced a non-exclusive agreement …

20 Participants Dosed in Semaglutide Trial; Data Due in November

Vivani Medical (VANI) reported its Q2 2026 financial results, highlighting the successful dosing of all 20 participants in its Phase 1 SLIM-1™ trial for NPM-139, a semaglutide implant, with top-line data expected in November 2026. The company also announced a non-exclusive agreement with Novo …

Tenon Medical (TNON) posts 127% Q2 2026 revenue growth amid higher net loss

Tenon Medical reported a significant revenue increase of 127% to $1.3 million in Q2 2026, driven by higher surgical procedures and the SImmetry®+ System, alongside an improved gross margin of 64%. Despite this growth, the company's net loss widened to $4.1 million, and it …

Tenon Medical Reports Second Quarter 2026 Financial Results

Tenon Medical (NASDAQ:TNON) announced its second quarter 2026 financial results, reporting a 127% increase in revenue to $1.3 million and a 232% increase in gross profit to $0.8 million compared to the prior year. The company also received FDA 510(k) clearance for its updated …

FDA Clears Tenon Medical System With Reusable Instruments

SBC Medical Group (NASDAQ:SBC) Posts Quarterly Earnings Results

Generate Biomedicines (GENB) Stock Price, News & Analysis

Generate Biomedicines (NASDAQ: GENB) utilizes machine learning and generative AI for novel therapeutic design and discovery. The company recently reported Q2 2026 earnings, missing analyst estimates, and has a "Moderate Buy" consensus rating with a price target of $25.40, suggesting a 62.4% upside. Its …

DiaMedica Therapeutics Inc. (DMAC) stock price, news, quote and history

This article provides a comprehensive overview of DiaMedica Therapeutics Inc. (DMAC), including its current stock price, financial statistics, historical data, and analyst insights. It highlights DMAC as a clinical-stage biopharmaceutical company focused on ischemic diseases, with its lead candidate DM199 in Phase 2/3 trials. …

Janus Henderson holds 11.1% of ICU Medical (ICUI) common stock via clients

Janus Henderson Group Ltd. has reported a beneficial ownership of 2,781,621 shares of ICU Medical, Inc. common stock, which constitutes 11.1% of the class. These shares are held through various Managed Portfolios where Janus Henderson's affiliated Asset Managers exercise investment and voting discretion, though …

Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake

Janus Henderson Group Ltd. has disclosed a 5.1% beneficial ownership stake in Revolution Medicines, Inc. (RVMD), holding 10,736,145 shares of common stock. These shares are managed across various client portfolios, with Janus Henderson exercising shared voting and dispositive power but disclaiming economic ownership, which …

Trading Systems Reacting to (UTMD) Volatility

This article analyzes the volatility of Utah Medical Products Inc. (NASDAQ: UTMD), highlighting a strong overweight bias across all sentiment horizons. It details three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, providing entry and exit points, targets, …

Praxis (PRAX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Marcio De'SouzaChief Financial Officer - Tim KellyPresident of Research and Development - Steve PetrouChief Operating Officer - Megan Sniecinski TAKEAWAYS Cash and …

Top Medical Properties Trust (MPT) Competitors 2026

All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy

Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio

Pediatrix Medical Group, Inc. MD is a physician services provider company that offers a range of services across various specialties, including obstetrics, maternal-fetal medicine and neonatology, complemented by multiple pediatric subspecialties. The company has gained 23.9% in the year-to-date period, outperforming the industry's 1.2% …

Fresenius Medical Care stock holds steady near $24 as investors digest latest capital market update

Fresenius Medical Care stock is trading near $24, with a slight decline of 0.67% on the NYSE and 0.28% in Europe, as investors analyze the company's latest capital market update. This update details recent share repurchases and trading activity, suggesting a strategy to optimize …

Strata Critical Medical (SRTA) Q2 2026 Earnings Call Transcript

Merit Medical Systems, Inc. (MMSI) Stock Forecasts

Argus has raised its target price for Merit Medical Systems Inc. (MMSI) to $100.00, citing the company's role as a medical equipment developer and manufacturer. The report, published on August 12, 2026, highlights MMSI's products for interventional cardiology, radiology, and endoscopy procedures. Full access …

Rockwell Medical Q2 2026 slides: margin gains fuel profitability push

Rockwell Medical (NASDAQ:RMTI) released its Q2 2026 results, showing 11% revenue growth and an 18% gross margin, despite narrowly missing Wall Street expectations. The company is advancing towards sustained profitability through operational improvements, customer diversification, and a strategic plan to exceed $100 million in …

Earnings call transcript: SBC Medical posts Q2 2026 revenue beat, EPS miss

SBC Medical Group Holdings reported mixed Q2 2026 results, exceeding revenue expectations with $49 million, a 13% year-on-year increase, but missing EPS forecasts at $0.10. The company highlighted a re-acceleration of growth following 2025 structural reforms, driven by clinic expansion, AI tool integration, and …

Earnings call transcript: NeuroOne Medical posts Q3 2026 revenue growth as shares fall

NeuroOne Medical Technologies reported a 16% year-over-year increase in Q3 2026 product revenue, reaching $2.0 million, driven by stronger sales of its OneRF brain ablation products and a 43% jump in orders. Despite revenue growth and improved gross margins, the company's net loss widened …

Journey Medical's (DERM) Buy Rating Reaffirmed at B. Riley Financial

B. Riley Financial has reaffirmed its "Buy" rating for Journey Medical (NASDAQ:DERM), increasing its price target from $12 to $15, which suggests a 133.28% potential upside. Despite mixed analyst opinions, the company recently surpassed quarterly expectations, reporting an adjusted loss of $0.01 per share …

Earnings call transcript: Rockwell Medical Q2 2026 revenue rises 11%

Rockwell Medical, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Operational Efficiency Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Rockwell Medical (Nasdaq: RMTI) grows Q2 2026 sales, tightens loss and reaffirms 2026 outlook

Rockwell Medical (RMTI) announced strong Q2 2026 results, with net sales increasing 11% year-over-year to $17.8 million and gross profit rising 30%. The company significantly narrowed its net loss to $1.2 million and generated positive operating cash flow of $2.1 million, strengthening its cash …